Adaptive Biotechnologies (ADPT) Scheduled to Post Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) will issue its quarterly earnings data on Tuesday, April 2nd.

Adaptive Biotechnologies (NASDAQ:ADPTGet Free Report) last issued its earnings results on Wednesday, February 14th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.02. The company had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $3.21 on Monday. The stock has a 50-day moving average of $3.70 and a 200-day moving average of $4.33. The company has a market cap of $465.74 million, a PE ratio of -2.06 and a beta of 1.27. Adaptive Biotechnologies has a one year low of $2.61 and a one year high of $9.08.

Insider Activity

In other Adaptive Biotechnologies news, SVP Stacy L. Taylor sold 13,381 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $45,896.83. Following the completion of the sale, the senior vice president now directly owns 166,287 shares of the company’s stock, valued at $570,364.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $166,948.39. Following the completion of the transaction, the chief executive officer now owns 2,576,701 shares of the company’s stock, valued at $8,838,084.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Stacy L. Taylor sold 13,381 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $45,896.83. Following the transaction, the senior vice president now directly owns 166,287 shares of the company’s stock, valued at approximately $570,364.41. The disclosure for this sale can be found here. Insiders sold 124,307 shares of company stock worth $428,090 in the last three months. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently made changes to their positions in ADPT. JPMorgan Chase & Co. increased its position in shares of Adaptive Biotechnologies by 17.7% during the first quarter. JPMorgan Chase & Co. now owns 329,115 shares of the company’s stock valued at $4,569,000 after acquiring an additional 49,451 shares in the last quarter. HighTower Advisors LLC bought a new stake in Adaptive Biotechnologies in the 1st quarter worth approximately $160,000. Citigroup Inc. grew its position in Adaptive Biotechnologies by 16.6% in the 1st quarter. Citigroup Inc. now owns 28,375 shares of the company’s stock worth $394,000 after purchasing an additional 4,047 shares during the period. PNC Financial Services Group Inc. grew its position in Adaptive Biotechnologies by 176.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,293 shares of the company’s stock worth $73,000 after purchasing an additional 3,380 shares during the period. Finally, Bank of Montreal Can bought a new stake in Adaptive Biotechnologies in the 1st quarter worth approximately $1,284,000. Institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. The Goldman Sachs Group cut their price target on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, February 16th. JPMorgan Chase & Co. lowered their price target on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating on the stock in a report on Thursday, February 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.25.

Get Our Latest Stock Analysis on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Recommended Stories

Earnings History for Adaptive Biotechnologies (NASDAQ:ADPT)

Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.